The Limited Times

Now you can see non-English news...

Corona vaccine: German company has big plans - "It is our goal ..."

2020-11-19T02:19:56.932Z


The corona vaccine from Biontech and Pfizer is due to be delivered soon. Biontech boss Ugur Sahin does not expect a return to normal until winter 2021.


The corona vaccine from Biontech and Pfizer is due to be delivered soon.

Biontech boss Ugur Sahin does not expect a return to normal until winter 2021.

  • The Mainz-based pharmaceutical company

    Biontech

    and its US partner

    Pfizer

    have developed a promising

    corona vaccine *

    .

    (see first report)

  • Biontech

    boss

    Ugur Sahin *

    does not expect a return to

    normal

    until winter 2021

    .

    (see first report)

  • The US pharmaceutical company

    Moderna

    has presented a

    corona vaccine

    with an

    effectiveness of 94.5 percent

    .

    (see update from November 16, 1:17 p.m.)

  • This news ticker is updated regularly.

Update from November 18, 11.09 a.m.:

The company

CureVac

from Tübingen has announced that it

wants to expand

its

European network in

order to be able to manufacture larger quantities of its vaccine candidate.

The preparations for the start of production and the technology transfer of the

corona vaccine candidate CVnCoV

, as the liquid is called, are underway.

"Based on this strategy, the company intends to significantly increase its existing production capacities for CVnCoV to up to 300 million cans in 2021 and up to 600 million cans in 2022, while at the same time reducing potential risks in the supply chain," the company said on Tuesday with.

In addition, a

large

production facility

funded

by the

European Investment Bank (EIB) is

currently being set up

at

CureVac's

headquarters

in

Tübingen

.

"It is our goal to increase the production capacity within a short period of time in order to ensure a stable supply of our vaccine candidate", explained production director

Florian von der Mülbe

.

The company is currently working with

experienced partners across Europe

to build a solid

production

network.

Geographical proximity is an important factor here in order to facilitate alignment and technology transfer.

CureVac

plans

to initiate

the pivotal

Phase 2b / 3

clinical trial by

the end of 2020.

Corona vaccine: EU Commission agrees contract with CureVac

Update from November 17, 10:40 a.m.:

The

EU Commission

has with the Tübingen company

CureVac

signed a contract to purchase

up to 405 million doses of corona vaccine

.

This was announced by Commission President

Ursula von der Leyen

on Monday afternoon in

Brussels

.

This is the fifth framework agreement with pharmaceutical companies that have a promising vaccine against the

coronavirus

under development.

We continue to work to secure safe & effective vaccines to end the pandemic.



I am glad to announce a new agreement to buy up to 405 million doses of a vaccine produced by the European company @CureVacRNAhttps: //t.co/H1gFQH7FAX

- Ursula von der Leyen (@vonderleyen) November 16, 2020

Corona: Vaccine from the US company Moderna can be stored well

Update from November 16, 3:36 p.m .:

The apparently effective

vaccine from

the US company

Moderna

can be stored for a comparatively long time at normal

refrigerator temperature

.

It is assumed that the agent

mRNA-1273 will

remain stable for 30 days at temperatures of 2 to 8 degrees, according to a statement on Monday.

Previously, a shelf life of seven days at these temperatures was assumed.

Moderna has

now announced that the preparation

mRNA-1273

can be stored

at

minus 20 degrees Celsius for

up to

six months

.

The vaccine could "be stored and transported at temperatures that are usually in existing pharmaceutical freezers and refrigerators," said

Juan Andres

of Moderna, according to the announcement.

The

vaccine is

stable for up to 12 hours

at 

room temperature

.

Corona vaccine: US expert Fauci enthusiastic about published data

The renowned US immunologist and corona expert 

Anthony Fauci

responded

 with enthusiasm to the

data published

by

Moderna

.

"These are obviously very exciting results," he said, according to 

CNN

.

"It doesn't get any better - 94.5 percent are really excellent," says 

Fauci

.

He estimates that the 

first vaccinations

 in the 

United States could start

 in 

December

 for 

high-risk groups

 , with the rest of the population more likely to be up by the end of April.

Corona: Moderna wants to apply for emergency approval for vaccine in the USA in the coming weeks

Update from November 16, 2:31 p.m.:

The

phase III study

for the

vaccine mRNA-1273 from

the US pharmaceutical company

Moderna

includes a total of

30,000 test subjects

.

Half of them received the

corona vaccine

, the other half act as a control group and receive a placebo.

So far, a total of 95 study participants have contracted

Covid-19

.

Of these, only 5 cases were actually vaccinated, 90 cases were diagnosed in the control group.

The

effectiveness of 94.5 percent is

calculated from this

.

This is about the extent to which the

vaccine

can prevent the disease.

So far there are no

data on the degree to which

mRNA-1273

prevents infection.

For

full vaccination protection

, two doses are necessary at intervals.

Moderna

plans to

apply for

emergency

approval from the US drug agency FDA

in the coming weeks

.

Applications to the

approval authorities in

other countries are also planned.

According to its own information, the company wants to be ready by the end of the year

to deliver

around

20 million vaccine doses

to the

USA

if it is

approved

.

Up to

a billion cans

are

expected to be

manufactured in the

coming year

.

Corona vaccine: EMA starts testing for Moderna vaccine

Update from November 16, 1:53 p.m.:

The

European Medicines Agency (EMA)

 has started the

test procedure

for a

corona vaccine

from

Moderna Biotech

in Spain, a spin-off of the US company

Moderna

.

The CHMP scientific committee of the EMA had given the green light for the so-called

rolling review process

after the first promising results from studies

, the authority announced on Monday in

Amsterdam

.

Because the data is already evaluated as soon as they are available, and not only after a formal application has been made for marketing authorization, which can

process

up to the

approval

review process Rolling considerably with a

shortened

are.

With this

accelerated approval process

, pharmaceutical companies can

report

their

vaccine candidates

to

the EMA

in a kind of pre-approval process during the

clinical trial

phase

.

The data from ongoing studies are then submitted on an ongoing basis and assessed by the EMA.

In addition to

Moderna

,

Biontech / Pfizer

and the British-Swedish company

Astrazeneca

are currently

taking

this route.

How long the review will take is unclear.

As soon as there is sufficient evidence for the

effectiveness

as well as the

safety

and

quality of

the

vaccine

, approval for the

European market can be

applied for.

Corona vaccine: Moderna presents a vaccine with an effectiveness of 94.5 percent

Update from November 16, 1:17 p.m.:

With the US pharmaceutical company

Moderna

, another

manufacturer relevant

for

Europe has

submitted

relevant data for its

corona vaccine

.

The RNA vaccine has an

effectiveness of 94.5 percent

, it said in a statement from

Moderna

on Monday.

The EU Commission is negotiating with the US group about the delivery of up to

160 million vaccine doses

.

We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study.


Read more: https://t.co/vYWEy8CKCv pic.twitter.com/YuLubU1tlx

- Moderna (@moderna_tx) November 16, 2020

Corona vaccine: Biontech boss Sahin expects a return to normal at the end of 2021

First report from November 16:

Mainz - The number of infections with the

corona

virus

remains high

in

Germany

during the

second wave * of

the pandemic

.

A

partial lockdown

is already in place, on Monday Chancellor

Angela Merkel

and the Prime Minister will again discuss an adjustment of the

measures

.

Many people hope for a return to

normality

rests on the

corona vaccine

, which was developed by the Mainz-based pharmaceutical company

Biontech

and its US partner

Pfizer

.

The

Biontech CEO

and co-founder

Ugur Sahin *

does not

expect

a return to

normal

during the

Corona crisis

until winter 2021

.

In order to achieve this goal, a high

vaccination rate

against the

coronavirus * is

"absolutely essential" by autumn, said Sahin in an interview with the British television broadcaster

BBC

on Sunday

.

"I am confident that this will happen," he said.

Looking ahead to this year's cold season, the vaccine developer's board added: "This winter will be tough."

For the

time being, i.e. this winter, the

vaccine

will not have a major impact on the number of

infections

.

Sahin

announced that if everything continues to go well, the

vaccine will be delivered

from "late this year, early next year".

A medium-term goal of

Biontech

is to make more than

300 million cans available

worldwide

by April

.

"That could have an effect," said Sahin in relation to the

Corona situation *

.

Profile: Ugur Sahin and Ozlem Tureci



The Turkish-German husband-and-wife team responsible for the development of the world's first effective coronavirus vaccine.https: //t.co/kIPUNnu0Sz

- BBC Current Affairs (@BBC_CurrAff) November 15, 2020

Corona vaccine: Emergency approval should be applied for in November

The German company

Biontech *

and the US pharmaceutical

company Pfizer were the

first western manufacturers to present promising data from their

clinical tests

last Monday

.

Accordingly, your

vaccine

offers

more than

90 percent protection

against the

coronavirus *

.

According to reports, the companies want to

apply for

an

emergency

approval for the

corona vaccine

from the US Food and Drug Administration

this month

.

On Wednesday, the

EU Commission

formally

approved

a framework agreement with the companies

Biontech

and

Pfizer

for up to

300 million vaccine doses

.

Similar contracts are already in place with vaccine developers Johnson & Johnson, Astrazeneca and Sanofi-GSK for a total of up to 800 million doses of a

corona vaccine

.

Two other companies are in talks, said EU Health Commissioner

Stella Kyriakides

.

None of the manufacturers has yet been

approved for a

vaccine

against the

coronavirus *

.

(ph / dpa) * Merkur.de is part of the Ippen-Digital editorial network

List of rubric lists: © picture alliance / Friso Gentsch / dpa

Source: merkur

All news articles on 2020-11-19

You may like

News/Politics 2024-03-18T14:18:09.201Z
News/Politics 2024-03-16T18:46:42.470Z

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.